Physicians’ experience in blood supply shortages and the top factors that impact the clinical, economic, and humanistic outcomes of patients with myelodysplastic syndromes in 5 European countries

References

• Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–2964.
   PubMed Web of Science ®Google Scholar
• Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26(6):1286–1292.
   PubMed Web of Science ®Google Scholar
• Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 2016;136(1):23–42.
   PubMed Web of Science ®Google Scholar
• Germing U, Oliva EN, Hiwase D, et al. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. HemaSphere. 2019;3(6):e314.
   PubMed Web of Science ®Google Scholar
• Smith BD, Mahmoud D, Dacosta-Byfield S, et al. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma. 2014;55(5):1119–1125.
   PubMed Web of Science ®Google Scholar
• Lucioni C, Finelli C, Mazzi S, et al. Costs and quality of life in patients with myelodysplastic syndromes. Am J Blood Res. 2013;3(3):246–259.
   PubMedGoogle Scholar
• Oliva EN, Finelli C, Santini V, et al. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136–147.
   PubMedGoogle Scholar
• Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Maciejewski JP, List AF, et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011;16(6):904–911.
   PubMed Web of Science ®Google Scholar
• European Commission. Summary of the Conference on the Evaluation of the EU Legislation on Blood, Tissues and Cells. 2019; [cited 2022 March 2]. Available from: https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/btc_evaluationconference_sr_en.pdf.
   Google Scholar
• Gupta S, Kulasekararaj AG, Costantino H, et al. Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians’ perspective. Cancer Rep. 2022;2022:e1680.
   Google Scholar
• World Health Organization. Global Database on Blood Safety: Summary Report 2011. 2011; [cited 2022 March 2]. Available from: https://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_2011.pdf.
   Google Scholar
• Grecuccio C, Ferraro M, Colafelice M, et al. Blood transfusion practice: state of the art on promoting blood donation in Italy. Biomed Prev. 2017;1:89.
   Google Scholar
• Vijenthira A, Starkman R, Lin Y, et al. Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome. Transfusion. 2022;62(7):1355–1364.
   PubMed Web of Science ®Google Scholar
• Koutsavlis I. Transfusion thresholds, quality of life, and current approaches in myelodysplastic syndromes. Anemia. 2016;2016:8494738.
   PubMed Web of Science ®Google Scholar
• Wood EM, McQuilten ZK. Outpatient transfusions for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2020;2020(1):167–174.
   PubMedGoogle Scholar
• Bowen DT. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients. Semin Oncol. 2005;32(4 Suppl 5):S16–S23.
   PubMed Web of Science ®Google Scholar
• Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096–1107.
   PubMed Web of Science ®Google Scholar
• Palacios-Berraquero ML, Alfonso-Piérola A. Current therapy of the patients with MDS: walking towards personalized therapy. J Clin Med. 2021;10(10):2107.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–655.
   PubMed Web of Science ®Google Scholar
• Wehmeyer J, Zaiss M, Losem C, et al. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). Eur J Haematol. 2018;101(6):766–773.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kotsianidis I, Bouchla A, et al. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol. 2020;11:2040620720966121.
   Web of Science ®Google Scholar
• Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–411.
   PubMed Web of Science ®Google Scholar
• Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–1392.
   PubMed Web of Science ®Google Scholar
• Falantes JF, Calderón C, Márquez Malaver FJ, et al. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with <10% marrow blasts and non-unfavorable cytogenetic categories. Clin Lymphoma Myeloma Leuk. 2013;13(2):144–152.
   PubMed Web of Science ®Google Scholar
• Müller MM, Geisen C, Zacharowski K, et al. Transfusion of packed red cells: indications, triggers and adverse events. Dtsch Arztebl Int. 2015;112(29–30):507–517; quiz 518.
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Gattermann N, Lee JW, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 2013;11(1):108–122.
   PubMed Web of Science ®Google Scholar
• Tsante A, Papandreadi A, Tsantes AG, et al. Seeking strategies to optimize blood utilization: the preliminary experience with implementing a patient blood management program in a Greek tertiary hospital. J Clin Med. 2021;10(10):2141.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global Status Report on Blood Safety and Availability 2016. Geneva: WHO; 2017. Licence No. CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Fong IW. Current trends and concerns in infectious diseases: emerging infectious diseases of the 21st century. New York: Springer; 2020. Chapter 8, Blood transfusion-associated infections in the twenty-first century: new challenges; p. 191–215.
   Google Scholar
• Mahecic TT, Dünser M, Meier J. RBC transfusion triggers: is there anything new? Transfus Med Hemother. 2020;47(5):361–368.
   PubMed Web of Science ®Google Scholar
• Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev. 2014;28(3):137–144.
   PubMed Web of Science ®Google Scholar